SynthesisActa medica academica2024

An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review.

Darmadi Darmadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.